Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450

Current Drug Metabolism

Volumn 15, Issue 7, 2014, Pages 651-679

  Niwa, Toshiro ^a   Imagawa, Yurie ^a   Yamazaki, Hiroshi ^b  

^a SHUJITSU UNIVERSITY   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antifungal agent; Azole; CYP51 (14 sterol demethylase); Cytochrome P450; Echinocandin; Inhibition

Indexed keywords

AMIODARONE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEBRISOQUINE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MEPHENYTOIN; MICAFUNGIN; MICONAZOLE; NIFEDIPINE; POSACONAZOLE; STEROL 14ALPHA DEMETHYLASE; TOLBUTAMIDE; UNINDEXED DRUG; VORICONAZOLE; ECHINOCANDIN; FUNGAL PROTEIN; PYRROLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; COMPETITIVE INHIBITION; DEALKYLATION; DEBENZYLATION; DISSOCIATION CONSTANT; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; ELIMINATION HALF-LIFE; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME METABOLISM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; DRUG INTERACTION; METABOLISM;

ANTIFUNGAL AGENTS; AZOLES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ECHINOCANDINS; FUNGAL PROTEINS; HUMANS;

EID: 84926301277     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200215666141125121511     Document Type: Article

References (124)

1. Pasqualotto, A.C.; Denning DW. New and emerging treatments for fungal infections. J. Antimicrob. Chemother., 2008, 61(Suppl 1), i19-30.
2. Lass-Flörl, C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs, 2011, 71(18), 2405-2419.
3. Kofla, G.; Ruhnke, M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur. J. Med. Res., 2011, 16(4), 159-166.
4. Chen, S.C.; Slavin, M.A.; Sorrell, T.C. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs, 2011, 71(1), 11-41.
5. Rendic, S. Summary of information on human P450 enzymes: human P450 metabolism data. Drug Metab. Rev., 2002, 34(1-2), 83-448.
6. Zhou, S.F.; Liu, J.P.; Chowbay, B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 2009, 41(2), 89-295.
7. Bourrié, M.; Meunier, V.; Berger, Y.; Fabre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther., 1996, 277(1), 321-332.
8. Sakaeda, T.; Iwaki, K.; Kakumoto, M.; Nishikawa, M.; Niwa, T.; Jin, J.S.; Nakamura, T.; Nishiguchi, K.; Okamura, N.; Okumura, K. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J. Pharm. Pharmacol., 2005, 57(6), 759-764.
9. Niwa, T.; Shiraga, T.; Takagi, A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull., 2005, 28(9), 1805-1808.
10. Niwa, T.; Inoue-Yamamoto, S.; Shiraga, T; Takagi, A. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol. Pharm. Bull., 2005, 28(9), 1813-1816.
11. Niwa, T.; Shiraga, T.; Yamasaki, S.; Ishibashi, K.; Ohno, Y.; Kagayama, A. In vitro activation of 7-benzyloxyresorufin Odebenzylation and nifedipine oxidation in human liver microsomes. Xenobiotica, 2003, 33(7), 717-729.
12. Niwa, T.; Inoue, S.; Shiraga, T.; Takagi, A. No inhibition of cytochrome P450 activities in human liver microsomes by sulpiride, an antipsychotic drug. Biol. Pharm. Bull., 2005, 28(1), 188-191.
13. Zhou, S.; Chan, E.; Lim, L.Y.; Boelsterli, U.A.; Li, S.C.; Wang, J.; Zhang, Q.; Huang, M.; Xu, A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab., 2004, 5(5), 415-442.
14. Draper, A.J.; Madan, A.; Parkinson, A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys., 1997, 341(1), 47-61.
15. Grime, K.H.; Bird, J.; Ferguson, D.; Riley, R.J. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur. J. Pharm. Sci., 2009, 36(2-3), 175-191.
16. Kozakai, K.; Yamada, Y; Oshikata, M.; Kawase, T.; Suzuki, E.; Haramaki, Y.; Taniguchi, H. Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms. Drug Metab. Pharmacokinet., 2014, 29(2),198-207.
17. Kunze, K.L.; Wienkers, L.C.; Thummel, K.E.; Trager, W.F. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos., 1996, 24(4), 414-421.
18. Brown, H.S.; Galetin, A.; Hallifax, D.; Houston, J.B. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin. Pharmacokinet., 2006, 45(10), 1035-1050.
19. Tassaneeyakul, W.; Birkett, D.J.; Miners, J.O. Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica, 1998, 28(3), 293-301.
20. von Moltke, L.L.; Greenblatt, D.J.; Duan, S.X.; Harmatz, J.S.; Wright, C.E.; Shader, R.I. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J. Clin. Psychopharmacol., 1996, 16(2), 104-112.
21. von Moltke, L.L.; Greenblatt, D.J.; Schmider, J.; Duan, S.X.; Wright, C.E.; Harmatz, J.S.; Shader, R.I. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol., 1996, 36(9), 783-791.
22. Kaneko, H.; Yamato, Y.; Hashimoto, T.; Ishii, I.; Shiraga, T.; Kawamura, A.; Terakawa, M.; Kagayama, A. Drug interactions of micafungin in vitro. Jpn. J. Chemother., 2002, 50 (Suppl. 1), 94-103.
23. Zhang, S.; Pillai, V.C.; Mada, S.R.; Strom, S.; Venkataramanan, R. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica, 2012, 42(5), 409-416.
24. Isoherranen, N.; Ludington, S.R.; Givens, R.C.; Lamba, J.K.; Pusek, S.N.; Dees, E.C.; Blough, D.K.; Iwanaga, K.; Hawke, R.L.; Schuetz, E.G.; Watkins, P.B.; Thummel, K.E.; Paine, M.F. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab. Dispos., 2008, 36(1), 146-154.
25. Yamazaki, H.; Nakamoto, M.; Shimizu, M.; Murayama, N.; Niwa, T. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br. J. Clin. Pharmacol., 2010, 69(6), 593-597.
26. Yang, J.; Atkins, W.M.; Isoherranen, N.; Paine, M.F.; Thummel, K.E. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clin. Pharmacol. Ther., 2012, 91(3), 442-9.
27. Walsky, R.L.; Astuccio, A.V.; Obach, R.S. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J. Clin. Pharmacol., 2006, 46(12), 1426-1438.
28. Shirasaka, Y.; Chang, S.Y.; Grubb, M.F.; Peng, C.C.; Thummel, K.E.; Isoherranen, N.; Rodrigues, A.D. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions. Drug Metab. Dispos., 2013, 41(8), 1566-1574.
29. Stresser, D.M.; Blanchard, A.P.; Turner, S.D.; Erve, J.C.; Dandeneau, A.A.; Miller, V.P.; Crespi, C.L. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab. Dispos., 2000, 28(12), 1440-1448.
30. Colburn, D.E.; Giles, F.J.; Oladovich, D.; Smith, J.A. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology, 2004, 9(3), 217-221.
31. Isoherranen, N.; Kunze, K.L.; Allen, K.E.; Nelson, W.L.; Thummel, K.E. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos., 2004, 32(10), 1121-1131.
32. Akiyoshi, T.; Saito, T.; Murase, S.; Miyazaki, M.; Murayama, N.; Yamazaki, H.; Guengerich, F.P.; Nakamura, K.; Yamamoto, K.; Ohtani, H. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. Drug Metab. Dispos., 2011, 39(4), 724-728.
33. Elsherbiny, M.E.; El-Kadi, A.O.; Brocks, D.R. The metabolism of amiodarone by various P450 isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J. Pharm. Pharm. Sci., 2008, 11(1), 147-159.
34. Baldwin, S.J.; Bloomer, J.C.; Smith, G.J.; Ayrton, A.D.; Clarke, S.E.; Chenery, R.J. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 1995, 25(3), 261-270.
35. Greenblatt, D.J.; Zhao, Y.; Venkatakrishnan, K.; Duan, S.X.; Harmatz, J.S.; Parent, S.J.; Court, M.H.; von Moltke, L.L. Mechanism of cytochrome P450-3A inhibition by ketoconazole. J. Pharm. Pharmacol., 2011, 63(2), 214-221.
36. Zhang, W.; Ramamoorthy, Y.; Kilicarslan, T.; Nolte, H.; Tyndale, R.F.; Sellers, E.M. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab. Dispos., 2002, 30(3), 314-318.
37. O'Reilly, R.A.; Goulart, D.A.; Kunze, K.L.; Neal, J.; Gibaldi, M.; Eddy, A.C.; Trager, W.F. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin. Pharmacol. Ther., 1992, 51(6), 656-667.
38. Wexler, D.; Courtney, R.; Richards, W.; Banfield, C.; Lim, J.; Laughlin, M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci., 2004, 21(5), 645-653.
39. Jeong, S.; Nguyen, P.D.; Desta, Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob. Agents Chemother., 2009, 53(2), 541-551.
40. Damle, B.D.; Dowell, J.A.; Walsky, R.L.; Weber, G.L.; Stogniew, M.; Inskeep, P.B. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob. Agents Chemother., 2009, 53(3), 1149-56.
41. Caspofungin Acetate (CANDIDAS®) application material, MSD, 2011. http://www.info.pmda.go.jp/shinyaku/P201200014/index.html (Accessed April 5, 2014).
42. Tran, T.H.; Von Moltke, L.L.; Venkatakrishnan, K.; Granda, B.W.; Gibbs, M.A.; Obach, R.S.; Harmatz, J.S.; Greenblatt, D.J. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab. Dispos., 2002, 30(12), 1441-1445.
43. Sakaeda, T.; Nakamura, T.; Okumura, K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull., 2002, 25(11), 1391-1400.
44. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P.B.; Daly, A.; Wrighton, S.A.; Hall, S.D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M.S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 2001, 27(4), 383-391.
45. Niwa, T.; Murayama, N.; Emoto, C.; Yamazaki, H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr. Drug Metab., 2008, 9(1), 20-33.
46. Niwa, T.; Murayama, N.; Yamazaki, H. Comparison of the contributions of cytochromes P450 3A4 and 3A5 in drug oxidation rates and substrate inhibition, J. Health Sci., 2010, 56(3), 239-256.
47. Niwa, T.; Yasumura, M.; Murayama, N.; Yamazaki, H. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation. Drug Metab. Lett., 2014, 8(1), 43-50.
48. Niwa, T.; Murayama, N.; Yamazaki, H. Heterotropic cooperativity in oxidation mediated by cytochrome P450. Curr. Drug Metab., 2008, 9(5), 453-462.
49. Strushkevich, N.; Usanov, S.A.; Park, H.W. Structural basis of human CYP51 inhibition by antifungal azoles. J. Mol. Biol., 2010, 397(4), 1067-1078.
50. Aoyama, Y.; Noshiro, M.; Gotoh, O.; Imaoka, S.; Funae, Y.; Kurosawa, N.; Horiuchi, T.; Yoshida, Y. Sterol 14-demethylase P450 (P45014DM∗) is one of the most ancient and conserved P450 species. J. Biochem., 1996, 119(5), 926-933.
51. Park, H.G.; Lee, I.S.; Chun, Y.J.; Yun, C.H.; Johnston, J.B.; Montellano, P.R.; Kim, D. Heterologous expression and characterization of the sterol 14α-demethylase CYP51F1 from Candida albicans. Arch. Biochem. Biophys., 2011, 509(1), 9-15.
52. Warrilow, A.G.; Mullins, J.G.; Hull, C.M.; Parker, J.E.; Lamb, D.C.; Kelly, D.E.; Kelly, S.L. S279 point mutations in Candida albicans sterol 14α-demethylase (CYP51) reduce in vitro inhibition by fluconazole. Antimicrob. Agents Chemother., 2012, 56(4), 2099-2100.
53. Warrilow, A.G.; Parker, J.E.; Kelly, D.E.; Kelly, S.L. Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob. Agents Chemother., 2013, 57(3), 1352-1360.
54. Warrilow, A.G.; Melo, N.; Martel, C.M.; Parker, J.E.; Nes, W.D.; Kelly, S.L.; Kelly, D.E. Expression, purification, and characterization of Aspergillus fumigatus sterol 14α-demethylase (CYP51) isoenzymes A and B. Antimicrob. Agents Chemother., 2010, 54(10), 4225-4234.
55. Korosec, T.; Acimovic, J.; Seliskar, M.; Kocjan, D.; Tacer, K.F.; Rozman, D.; Urleb, U. Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14α-demethylase (CYP51). Bioorg. Med. Chem., 2008, 16(1), 209-221.
56. Ekins, S.; Mankowski, D.C.; Hoover, D.J.; Lawton, M.P.; Treadway, J.L.; Harwood, H.J. Jr. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab. Dispos., 2007, 35(3), 493-500.
57. Albengres, E.; Le Louët H.; Tillement J.P. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf., 1998, 18(2), 83-97.
58. Venkatakrishnan, K.; von Moltke, L.L.; Greenblatt, D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 2000, 38(2), 111-180.
59. Pea, F.; Furlanut, M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin. Pharmacokinet., 2001, 40(11), 833-868.
60. Blum, R.A.; Wilton, J.H.; Hilligoss, D.M.; Gardner, M.J.; Henry, E.B.; Harrison, N.J.; Schentag J.J. Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther., 1991, 49(4), 420-425.
61. Kumar, V.; Brundage, R.C.; Oetting, W.S.; Leppik, I.E.; Tracy, T.S. Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab. Dispos., 2008, 36(7), 1242-1248.
62. Hynninen, V.V.; Olkkola, K.T.; Leino, K.; Lundgren, S.; Neuvonen, P.J.; Rane, A.; Valtonen, M.; Vyyryläinen, H.; Laine, K. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of S-(+)-and R-(-)-Ibuprofen. Antimicrob. Agents Chemother., 2006, 50(6), 1967-1972.
63. Karonen, T.; Laitila, J.; Niemi, M.; Neuvonen, P.J.; Backman, J.T. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur. J. Clin. Pharmacol., 2012, 68(5), 681-688.
64. Black, D.J.; Kunze, K.L.; Wienkers, L.C.; Gidal, B.E.; Seaton, T.L.; McDonnell, N.D.; Evans, J.S.; Bauwens, J.E.; Trager, W.F. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab. Dispos., 1996, 24(4), 422-428.
65. Kakuda, T.N.; Van Solingen-Ristea, R.; Aharchi, F.; Smedt, G.D.; Witek, J.; Nijs, S.; Vyncke, V.; Hoetelmans, R.M. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers. J. Clin. Pharmacol., 2013, 53(1):41-50.
66. Kang, B.C.; Yang, C.Q.; Cho, H.K.; Suh, O.K.; Shin, W.G. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm. Drug Dispos., 2002, 23(2), 77-81.
67. Saari, T.I,; Laine, K.; Bertilsson, L.; Neuvonen, P.J.; Olkkola, K.T. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur. J. Clin. Pharmacol., 2007, 63(10), 941-949.
68. Olkkola, K.T.; Ahonen, J.; Neuvonen, P.J. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg., 1996, 82(3), 511-516.
69. Ahonen, J.; Olkkola, K.T.; Neuvonen, P.J. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur. J. Clin. Pharmacol., 1997, 51(5), 415-419.
70. Cato, A. 3rd.; Cao, G.; Hsu, A.; Cavanaugh, J.; Leonard, J.; Granneman, R. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab. Dispos., 1997, 25(9), 1104-1106.
71. Koks, C.H.; Crommentuyn, K.M.; Hoetelmans, R.M.; Burger, D.M.; Koopmans, P.P.; Mathôt, R.A.; Mulder, J.W.; Meenhorst, P.L.; Beijnen, J.H. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br. J. Clin. Pharmacol., 2001, 51(6), 631-635.
72. Sud, K.; Singh, B.; Krishna, V.S.; Thennarasu, K.; Kohli, H.S.; Jha. V.; Gupta. K.L.; Sakhuja. V. Unpredictable cyclosporin - fluconazole interaction in renal transplant recipients. Nephrol. Dial. Transplant., 1999, 14(7), 1698-1703.
73. Kivistö, K.T.; Kantola, T.; Neuvonen, P.J. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol., 1998, 46(1), 49-53.
74. Hynninen, V.V.; Olkkola, K.T.; Bertilsson, L.; Kurkinen, K.J.; Korhonen, T.; Neuvonen, P.J.; Laine, K. Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. Antimicrob. Agents Chemother., 2009, 53(2), 587-592.
75. Niemi, M.; Tornio, A.; Pasanen, M.K.; Fredrikson, H.; Neuvonen, P.J.; Backman, J.T. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur. J. Clin. Pharmacol., 2006, 62(6), 463-72.
76. Shon, J.H.; Yeo, C.W.; Liu, K.H.; Lee, S.S.; Cha, I.J.; Shin, J.G. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. J. Clin. Pharmacol., 2010, 50(2), 195-204.
77. Tapaninen, T.; Backman, J.T.; Kurkinen, K.J.; Neuvonen, P.J.; Niemi, M. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renininhibiting effect of aliskiren. J. Clin. Pharmacol., 2011, 51(3), 359-367.
78. Neuvonen, P.J.; Jalava, K.M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther., 1996, 60(1), 54-61.
79. Neuvonen, P.J.; Kantola, T.; Kivistö, K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther., 1998, 63(3), 332-341.
80. Olkkola, K.T.; Backman, J.T.; Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther., 1994, 55(5), 481-485.
81. Ahonen, J.; Olkkola, K.T.; Neuvonen, P.J. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br. J. Clin. Pharmacol., 1995, 40(3), 270-272.
82. Backman, J.T.; Kivistö, K.T.; Olkkola, K.T.; Neuvonen, P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol., 1998, 54(1), 53-58.
83. Templeton, I.; Peng, C.C.; Thummel, K.E.; Davis, C.; Kunze, K.L.; Isoherranen, N. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin. Pharmacol. Ther., 2010, 88(4), 499-505.
84. Yu, K.S.; Cho, J.Y.; Jang, I.J.; Hong, K.S.; Chung, J.Y.; Kim, J.R.; Lim, H.S.; Oh, D.S.; Yi, S.Y.; Liu, K.H.; Shin, J.G.; Shin, S.G. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin. Pharmacol. Ther., 2004, 76(2), 104-112.
85. Lukkari, E.; Juhakoski, A.; Aranko, K.; Neuvonen, P.J. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Eur. J. Clin. Pharmacol., 1997, 52(5), 403-406.
86. Kaukonen, K.M.; Olkkola, K.T.; Neuvonen, P.J. Itraconazole increases plasma concentrations of quinidine. Clin. Pharmacol. Ther., 1997, 62(5), 510-517.
87. Varhe, A.; Olkkola, K.T.; Neuvonen, P.J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther., 1994, 56(6 Pt 1), 601-607.
88. Martin, P.; Oliver, S.; Robertson, J.; Kennedy, S.J.; Read, J.; Duvauchelle, T. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R. D., 2011, 11(1), 37-51.
89. Krishnaiah, Y.S.; Satyanarayana, S.; Visweswaram, D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br. J. Clin. Pharmacol., 1994, 37(2), 205-207.
90. Böttiger, Y.; Tybring, G.; Götharson, E.; Bertilsson, L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin. Pharmacol. Ther., 1997, 62(4), 384-391.
91. Floren, L.C.; Bekersky, I.; Benet, L.Z.; Mekki, Q.; Dressler, D.; Lee, J.W.; Roberts, J.P.; Hebert, M.F. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther., 1997, 62(1), 41-49.
92. Krishna, G.; Moton, A.; Ma, L.; Savant, I.; Martinho, M.; Seiberling, M.; McLeod, J. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin. Ther., 2009, 31(2), 286-298.
93. Moton, A.; Ma, L.; Krishna, G.; Martinho, M.; Seiberling, M.; McLeod, J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr. Med. Res. Opin., 2009, 25(3), 701-707.
94. Purkins, L.; Wood, N.; Ghahramani, P.; Love, E.R.; Eve, M.D.; Fielding, A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol., 2003, 56 (Suppl 1), 37-44.
95. Hynninen, V.V.; Olkkola, K.T.; Leino, K.; Lundgren, S.; Neuvonen, P.J.; Rane, A.; Valtonen, M.; Laine, K. Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam. Clin. Pharmacol., 2007, 21(6), 651-656.
96. Jeu, L.; Piacenti, F.J.; Lyakhovetskiy, A.G.; Fung, H.B. Voriconazole. Clin. Ther., 2003, 25(5), 1321-1381.
97. Romero, A.J.; Le Pogamp, P.; Nilsson, L.G.; Wood, N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin. Pharmacol. Ther., 2002, 71(4), 226-234.
98. Purkins, L.; Wood, N.; Kleinermans, D.; Love, E.R. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br. J. Clin. Pharmacol., 2003, 56 (Suppl 1), 62-68.
99. Stone, J.A.; Migoya, E.M.; Hickey, L.; Winchell, G.A.; Deutsch, P.J.; Ghosh, K.; Freeman, A.; Bi, S.; Desai, R.; Dilzer, S.C.; Lasseter K.C.; Kraft, W.K.; Greenberg, H.; Waldman, S.A. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother., 2004, 48(11), 4306-4314.
100. Hebert, M.F.; Townsend, R.W.; Austin, S.; Balan, G.; Blough, D.K.; Buell, D.; Keirns, J.; Bekersky, I. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol., 2005, 45(8), 954-960.
101. Hebert, M.F.; Blough, D.K.; Townsend, R.W.; Allison, M.; Buell, D.; Keirns, J.; Bekersky, I. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol., 2005, 45(9), 1018-1024.
102. Bajpai, M.; Roskos, L.K.; Shen, D.D.; Levy, R.H. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos., 1996, 24(12), 1401-1403.
103. Ieiri, I.; Mamiya, K.; Urae, A.; Wada, Y.; Kimura, M.; Irie, S.; Amamoto, T.; Kubota, T.; Yoshioka, S.; Nakamura, K.; Nakano, S.; Tashiro, N.; Higuchi, S. Stereoselective 4α-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. Br. J. Clin. Pharmacol., 1997, 43(4), 441-445.
104. Kaminsky, L.S.; Zhang, Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther., 1997, 73(1), 67-74.
105. Yamazaki, H.; Shimada, T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers. Biochem. Pharmacol., 1997, 54(11), 1195-1203.
106. Debruyne, D.; Ryckelynck, J.P. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet., 1993, 24(1), 10-27.
107. Ahonen, J.; Olkkola, K.T.; Takala, A.; Neuvonen, P.J. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol. Scand., 1999, 43(5), 509-514.
108. Sud, K.; Singh, B.; Krishna, V.S.; Thennarasu, K.; Kohli, H.S.; Jha, V.; Gupta, K.L.; Sakhuja, V. Unpredictable cyclosporin- fluconazole interaction in renal transplant recipients. Nephrol. Dial. Transplant., 1999, 14(7), 1698-1703.
109. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. 26/07/2013. http://www. ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2 013/07/news-detail-001855.jsp&mid=WC0b01ac058004d5c1
110. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 26/07/2013. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm
111. Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos., 1998, 26(6), 552-561.
112. Marr, K.A.; Hachem, R.; Papanicolaou, G.; Somani, J.; Arduino, J.M.; Lipka, C.J.; Ngai, A.L.; Kartsonis, N.; Chodakewitz, J.; Sable, C. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl. Infect. Dis., 2004, 6(3), 110-116.
113. Sable, C.A.; Nguyen, B.Y.; Chodakewitz, J.A.; DiNubile, M.J. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl. Infect. Dis., 2002, 4(1), 25-30.
114. Ullmann, A.J. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opin., 2003, 19(4), 263-271.
115. Ito, K.; Iwatsubo, T.; Kanamitsu, S.; Ueda, K.; Suzuki, H.; Sugiyama, Y. Prediction of pharmacokinetic alterations caused by drugdrug interactions: metabolic interaction in the liver. Pharmacol. Rev., 1998, 50(3), 387-412.
116. Ito, K.; Iwatsubo, T.; Kanamitsu, S.; Nakajima, Y.; Sugiyama, Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 461-499.
117. Azuma, J.; Nakahara, K.; Kagayama, A.; Okuma, T.; Kawamura, A.; Mukai, T. Pharmacokinetic study of micagungin. Jpn. J. Chemother., 2002, 50 (Suppl. 1), 155-184.
118. Pearson, M.M.; Rogers, P.D.; Cleary, J.D.; Chapman, S.W. Voriconazole: a new triazole antifungal agent. Ann. Pharmacother., 2003, 37, 420-432.
119. Yamato Y.; Kaneko H.; Hashimoto T.; Katashima M.; Ishibashi, K.; Kawamura A.; Terakawa, M.; Kagayama, A. Pharmacokinetics of the antifungal drug micafungin in mice-rats and dogs-and its in vitro protein binding and distribution to blood cells. Jpn. J. Chemother., 2002, 50 (Suppl. 1), 74-79.
120. Lin, J.H.; Chiba M.; Baillie, T.A. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev., 1999, 51(2), 135-158.
121. Horton, C.M.; Freeman, C.D.; Nolan, P.E. Jr; Copeland, J.G. 3rd. Cyclosporine interactions with miconazole and other azoleantimycotics: a case report and review of the literature. J. Heart Lung Transplant., 1992, 11(6), 1127-1132.
122. Pang, K.S.; Rowland, M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm., 1977, 5(6), 625-653.
123. Wilkinson, G.R.; Shand, D.G. Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther., 1975, 18(4), 377-390.
124. Benet, L.Z.; Hoener, B.A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther., 2002, 71(3), 115-121.